Enzo Biochem, Inc. (NYSE:ENZ) an integrated diagnostic bioscience company, is reporting first quarter earnings results on Wednesday 9th December 2020, after market close.
The Company Outlook
Revenue for 1Q21 are expected in a range of $ 27.00 million ~ $ 27.00 million
Click Here For More Historical Outlooks Of Enzo Biochem, Inc.
Previous Quarter Performance
Enzo Biochem, Inc. unveiled loss for the fourth quarter of $ 0.07 per share, from the revenue of $ 19.53 million. The quarterly revenues decreased 6.64 percent compared with the same quarter last year. The consensus estimates are $ 20.92 million in revenue The top line results fell short of analysts by $ 1.39 million or 6.64 percent.
Stock Performance
Shares of Enzo Biochem, Inc. traded up $ 0.02 or 0.84 percent on Tuesday, reaching $ 2.41 with volume of 212.60 thousand shares. Enzo Biochem, Inc. has traded high as $ 2.45 and has cracked $ 2.36 on the downward trend
According to the previous trading day, closing price of $ 2.41, representing a 53.21 % increase from the 52 week low of $ 1.56 and a 50.72 % decrease over the 52 week high of $ 4.85.
The company has a market capital of $ 118.03 million and is part of the Healthcare sector and Diagnostics & Research industry.
Enzo Biochem, Inc., an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment manufactures, develops, and markets products and tools to clinical research, drug development, and bioscience research customers.
